Pharmafile Logo

Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care

September 24, 2025 |  

Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.

Voices-of-Oncology-Inizio

With over 30 years of deep-rooted expertise in oncology, we partner with our clients at each pivotal moment in their journey, unlocking value through a connected suite of capabilities. Today, we’re proud to announce that a number of our leaders in Inizio have been featured in Forbes’ Voices of Oncology, a collaboration that reflects our commitment to advancing cancer care.

Launching September 9, the ‘Voice of Innovation Partners’ chapter in Forbes’ ‘Voices of Oncology’ features contributions from:

Accelerating innovation in oncology through collaboration, data & technology

The ‘Voice of Innovation Partners’ chapter explores how innovation partners like Inizio harness advanced data analytics, cutting-edge technology, and cross-sector collaboration to:

  • Simplify complex challenges in oncology
  • Enhance decision-making across the cancer care continuum
  • Improve patient outcomes through real-world impact

The book is a powerful collection of insights from global experts and thought leaders, offering a shared perspective on how we can work better together to shape the future of oncology. Voices of Oncology is an initiative of the Oncology Voice Network (OVN), a new platform built to spark connection, share knowledge, and amplify solutions across pharma, biotech, academia, and patient advocacy.

Pre-order now: Forbes’ Voices of Oncology

Available to pre-order now via Amazon – explore the Voices of Oncology here. If you’re looking for a partner who can turn knowledge into action and accelerate the journey from breakthrough science to real-world impact, learn more about us.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Pegasus Wins ‘Consultancy of the Year’ at Communiqué Awards 2014

Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...